NCT07008833尚未招募不适用
Randomized, Non-inferiority Study Comparing Radiochemotherapy Versus Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer
Brazilian Clinical Research Institute1 个研究点 分布在 1 个国家目标入组 336 人开始时间: 2026年6月1日最近更新:
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 336
- 试验地点
- 1
- 主要终点
- Metastasis-free survival
研究概览
简要总结
Your text is mostly clear and well-structured. Here's a slightly polished version for improved clarity and flow:
This is a randomized, non-inferiority study comparing radiochemotherapy to radical cystectomy in patients with muscle-invasive bladder cancer. The primary outcome is the evaluation of the non-inferiority of metastasis-free survival between the two treatments.
The study population includes individuals of both sexes, aged 18 years and older, diagnosed with pure or predominant urothelial carcinoma. Participants will be randomized in a 1:1 ratio, with Arm 1 receiving maximal TURBT followed by neoadjuvant chemotherapy and radiotherapy, and Arm 2 receiving TURBT followed by neoadjuvant chemotherapy with cisplatin, followed by radical cystectomy and bilateral pelvic lymphadenectomy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
盲法说明
Clinical outcomes will be independently ascertained by a Clinical Events Committee, whose members will not be aware of the study arm.
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients ≥ 18 years of age.
- •Pure or predominant urothelial carcinoma (including other histologic subtypes, with the exception of small cell carcinoma, as a minority component).
- •Performance status of 0 to 1, according to the Eastern Cooperative Oncology Group (ECOG) criteria.
- •Life expectancy of ≥ 3 months.
- •Histologically confirmed T2, T3, or T4a stage bladder cancer (pure or predominant urothelial carcinoma) cN0 or cN1 or cN2 (if lymph nodes within the surgical and radiation fields and size ≤ 2 cm).
- •Patients who are candidates for neoadjuvant cisplatin and have undergone TURBT (preferably maximal) prior to treatment.
- •Adequate bladder function (defined as the ability to store and void urine effectively, without symptoms of dysfunction or incontinence).
- •Neutrophil count ≥ 1500/mm³.
- •Platelet count ≥ 100,000/mm³.
- •Hemoglobin count > 10 g/dL.
- •Glomerular filtration rate greater than 40 mL/min.
- •Serum bilirubin < 1.5 times the upper limit of the normal reference range and SGOT and SGPT < 1.5 times the upper limit of the normal reference range.
- •Absence of comorbidities that contraindicate treatment.
- •Capable of giving signed and dated informed consent prior to any mandatory study-specific procedures, sampling, and analyses, which includes compliance with the requirements and restrictions listed in the informed consent form and study protocol.
- •For inclusion in i) optional exploratory genetic research and ii) optional biomarker research, patients must meet the following criteria:
- •Provide informed consent for genetic research prior to sample collection.
- •Provide informed consent for biomarker research prior to sample collection.
- •If a patient declines to participate in optional biomarker research, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the study.
排除标准
- •Presence of multiple primary tumors or multiple foci of carcinoma in situ (CIS) (including in the upper tract) that are not candidates for bladder preservation with radiochemotherapy (definition at the discretion of the investigator).
- •Age > 80 years.
- •Pure adenocarcinoma or pure squamous carcinoma or pure small cell or large cell neuroendocrine carcinoma, micropapillary, sarcomatoid or nested.
- •Metastatic or unresectable disease.
- •Sensory neuropathy Grade ≥
- •Hearing impairment Grade ≥
- •Having a known additional malignancy that has progressed or required active treatment in the last 5 years, except superficial bladder cancer and/or carcinoma in situ, basal cell carcinoma of the skin or carcinoma in situ of the cervix.
- •Clinically significant cardiovascular disease - functional class III-IV according to the New York Heart Association (NYHA) Classification of heart failure.
- •Patients considered to be at high medical risk due to severe and uncontrolled disease, active or non-malignant systemic disease, and severe or potentially severe infection that may affect response to treatment or increase the risk of adverse events.
- •Immunocompromised patients.
- •Inflammatory bowel disease.
- •Patients with known active hepatitis (i.e., hepatitis B or C).
- •Patients receiving any prior systemic chemotherapy in the last 5 years for other tumors and at any time for muscle-invasive bladder cancer.
- •Patients who have received prior systemic immunotherapy at any time, either in the setting of non-muscle-invasive bladder cancer or in treatment for other types of cancer.
- •Prior pelvic radiotherapy.
- •Patients, male or female, who do not agree to use an effective method of contraception throughout treatment and until 6 months after discontinuation of treatment.
- •Women who are pregnant or currently breastfeeding.
- •The investigator's judgment that the patient should not participate in the study if the patient is unlikely to comply with the procedures, restrictions, and requirements.
- •19. Prior Randomization to the present study.
研究组 & 干预措施
Arm 1
Other
Maximum TURBT + neoadjuvant chemotherapy with cisplatin + radiotherapy
干预措施: Radiochemotherapy (Procedure)
Arm 2
Other
TURBT + neoadjuvant chemotherapy with cisplatin + radical cystectomy, bilateral pelvic lymphadenectomy + reconstruction
干预措施: Radical cystectomy (Procedure)
结局指标
主要结局
Metastasis-free survival
时间窗: The time from the start of treatment until detection of 230 metastases in other organs or tissues outside the bladder (including pelvic lymph nodes).or until death from any cause of the patient, estimated to be up to 8 years
The primary outcome is the assessment of the non-inferiority of metastasis-free survival between radiochemotherapy and radical cystectomy.
次要结局
- Overall survival(The duration from treatment initiation until the study accrues 230 patients with a primary event, or 6 years of follow-up)
- Muscle-invasive bladder cancer-free survival(The duration from treatment initiation until the study accrues 230 patients with a primary event, or 6 years of follow-up)
- Incidence of tumors in the upper tract (in both arms)(The duration from treatment initiation until the study accrues 230 patients with a primary event, or 6 years of follow-up)
- Adverse Events assessment(The duration from treatment initiation until the study accrues 230 patients with a primary event, or 6 years of follow-up)
- Quality of Life assessment(The duration from treatment initiation until the study accrues 230 patients with a primary event, or 6 years of follow-up)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Safety and Performance Investigation of a New 1-piece Ostomy Product Compared to Standard of Care 1-piece in Subjects With IleostomyIleostomy - StomaNCT01994863Coloplast A/S23
已完成
不适用
Disposable-Syringe Jet Injector for Measles-Mumps-Rubella vaccine (DSJI MMR) studyISRCTN04280032Bio-Manguinhos/Fiocruz (Brazil)582
已完成
不适用
ormothermic versus hypothermic cardiopulmonary bypass in paediatric open heart surgeryISRCTN93129502niversity Hospitals Bristol NHS Foundation Trust (UK)110
尚未招募
4 期
A post marketing surveillance trial to study the safety and efficacy of two drugs, Neupeg and Neulastim in female patients with advanced breast cancerCTRI/2010/091/000109Intas Biopharmaceuticals Limited100
进行中（未招募）
1 期
A Randomized, Open-label, Comparative Evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy.iver allograft recipients under maintenance therapyEUCTR2004-000935-27-CZWyeth Research Division of Wyeth Pharmaceuticals Inc.Clinical Research & Development Department600